OTHER GROUP COMPANIES
market

Torrent Pharma introduces Molnupiravir under brand name 'Molnutor' in India

Molnupiravir is the oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA).

December 28, 2021 4:25 IST | India Infoline News Service
Torrent Pharma on Tuesday has announced that it is introducing MSD (a trade name of Merck & Co., Inc, Kenilworth, NJ, USA) and Ridgeback’s molnupiravir under the brand name Molnutor in India.

Earlier this year, Torrent Pharma inked a non-exclusive voluntary licensing pact with MSD, granting rights to Torrent Pharma for manufacturing, distribution and marketing of Molnupiravir in more than 100 low-and middle-income markets including India for treatment of COVID-19.

The Drugs Controller General of India (DCGI), based on the review of clinical data of Molnupiravir has approved the drug for the treatment of COVID-19 in adults for restricted emergency use in India.

Molnupiravir is the oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and U.S. Food and Drug Administration (FDA) [for Emergency Use Authorisation (EUA)] for the treatment of mild-to-moderate COVID -19 in adults.

Torrent Pharma ended at Rs3,140 apiece down by Rs8.95 or 0.28% on the BSE.

OPEN A DEMAT ACCOUNT & Get
FREE Benefits Worth 5,000

FEATURED ARTICLE

BLOGS

Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity